Mechanism of action of angiotensin-receptor blocking agents

Current Hypertension Reports

Volumn 1, Issue 4, 1999, Pages 289-295

  Siragy, Helmy M ^a   Bedigian, Martin ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL; ARTERIOSCLEROSIS; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPERTENSION; KIDNEY DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARTERIOSCLEROSIS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; KIDNEY DISEASES; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0033170550     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-999-0036-3     Document Type: Article

References (61)

1. Akasu M, Urata H, Kinoshita A, et al.: Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 1998, 32: 514-520.
2. Griendling KK, Lassegue B, Alexander RW: Angiotensin receptors and their therapeutic implications. Am Rev Pharmacol Toxicol 1996, 36: 281-306.
3. Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996, 334: 1649-1654.
4. Matsukawa T, Ichikawa I: Biological functions of angiotensin and its receptors. Ann Rev Physiol 1997, 59: 395-412.
5. Lazard D, Briend-Sutren MM, Villageois P, et al.: Molecular characterization and chromosome localization of a human angiotensin II AT2 receptor gene highly expressed in fetal tissues. Receptors Channels 1994, 2: 271-280.
6. Bottari SP, King IN, Reichlin S, et al.: The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Commun 1992, 183: 206-211.
7. Fischer TA, Singh K, Ohara DS, et al.: Role of AT1 and AT2 receptors in regulation of mapks and mkp-1 by ang II in adult cardiac myocytes. Am J Physiol 1998, 44:H906-H916.
8. Matsubara H, Inada M: Molecular insights into angiotensin II type 1 and type 2 receptors - expression, signaling and physiological function and clinical application of its antagonists. Endocr J 1998, 45: 137-150.
9. Bedecs K, Elbaz N, Sutren M, et al.: Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J 1997, 325: 449-454.
10. Song K, Allen AM, Paxinos G, Mendelsohn FA: Mapping of angiotensin II receptor subtype heterogeneity in rat brain. J Comp Neurol 1992, 316: 467-484.
11. Ozono R, Wang ZQ, Moore AF, et al.: Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 1997, 30: 1238-1246.
12. Herblin WF, Diamond SM, Timmermans PB: Localization of angiotensin II receptor subtypes in the rabbit adrenal and kidney. Peptides 1991, 12: 581-584.
13. Wang ZQ, Moore AF, Ozono R, et al.: Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart. Hypertension 1998, 32: 78-83.
14. Matsubara H, Sugaya T, Murasawa S, et al.: Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization. Nephron 1998, 80 25-34. (Pubitemid 28434688)
15. Lopez JJ, Lorell BH, Ingelfinger JR, et al.: Distribution and function of cardiac angiotensin AT(1)- and AT(2)-receptor subtypes in hypertrophied rat hearts. Am J Physiol 1994, 267:H844-H852.
16. Ohkubo N, Matsubara H, Nozawa Y, et al.: Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997, 96: 3954-3962.
17. Nio Y, Matsubara H, Murasawa S, et al.: Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995, 95: 46-54.
18. Janiak P, Pillon A, Prost JF, Vilaine JP: Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992, 20: 737-745.
19. Nakajima M, Hutchinson HG, Fujinaga M, et al.: The angiotensin II type 2 (AT2) receptor antagonizes the growt effects of the AT(1) receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995, 92:10663 10667.
20. Tanaka M, Ohnishi J, Ozawa Y, et al.: Characterization of angiotensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells. Biochem Biophys Res Commun 1995, 207: 593-598.
21. Stoll M, Steckelings UM, Paul M, et al.: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995, 95: 651-657.
22. Hein L, Barsh GS, Pratt RE, et al.: Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 1995, 377: 744-747.
23. Ichiki T, Labosky PA, Shiota C, et al.: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995, 377: 748-750.
24. Brunner HR, Laragh JH, Baer L, et al.: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972, 286: 441-449.
25. Biollaz J, Brunner HR, Gavras I, et al.: Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982, 4: 966-972.
26. Weber KT, Sun Y, Guarda E: Nonclassic actions of angiotensin II and aldosterone in nonclassic target tissue (the heart): relevance to hypertensive heart disease. In Hypertension: Pathophysiology, Diagnosis, and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995: 2203-2223.
27. Ritz E, Fliser D, Nowicki M: Hypertension and vascular disease as complications of diabetes. In Hypertension: Pathophysiology, Diagnosis, and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995: 2321-2334.
28. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327: 685-691.
29. Swedberg K, Kjekshus J: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 1988, 62:60A-66A.
30. Siragy HM, Carey RM: The subtype-2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997, 100: 264-269.
31. Siragy HM, Carey RM: The subtype-2 (AT2) receptor regulates renal cyclic GMP and AT1 receptor-mediated PGE2 production in conscious rats. J Clin Invest 1996, 97: 1978-1982.
32. Siragy HM, Carey RM: Protective role of the angiotensin AT2 receptor in renal wrap hypertension model. Hypertension, In press.
33. Gohlke P, Pees C, Unger T: AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998, 28: 349-356.
34. Yamada T, Horiuchi M, Dzau VJ: Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996, 93: 156-160.
35. Liu YH, Yang XP, Sharov VG, et al.: Effects of angiotensinconverting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997, 99: 1926-1935.
36. Cifkova R, Peleska J, Hradec J, et al.: Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens 1998, 12: 563-567.
37. Mimran A, Ruilope L, Kerwin L, et al.: A randomised, doubleblind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998, 12: 203-208.
38. Corea L, Cardoni O, Fogari R, et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996, 60: 341-346.
39. Goa KL, Wagstaff AJ: Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996, 51: 820-845.
40. Lewis EJ, Hunsicker LG, Bain RP, et al.: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329: 1456-1462.
41. The EUCLID Study Group: Randomised placebo-control trial of lisinopril in normotensive patients with insulindependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997, 349: 1787-1792.
42. Mogensen C: Diabetes mellitus and the kidney. Kidney Int 1982, 21: 673-675.
43. Adler S: Structure-function relationships associated with extracellular matrix alteration in diabetic glomerulopathy. J Am Soc Nephrol 1994, 5: 1165-1172.
44. Ziyadeh F: Renal tubular membrane and collagen type IV in diabetes mellitus. Kidney Int 1993, 43: 114-120.
45. Cooper ME: Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients. J Hypertens 1996, 14(suppl 6): 11-14.
46. Wu LL, Yang N, Roe CJ, et al.: Macrophage and myofibroblast proliferation in remnant kidney: role of angiotensin II. Kidney Int 1997, 63:S221-S225. (Pubitemid 28020477)
47. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Angiotensin II blockade decreases TGF-beta 1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997, 52: 660-673.
48. Bitt B, Segal R, Martinez FA, et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure. Evaluation of Losartan in the Elderly Study (ELITE). Lancet 1997, 349: 747-752.
49. Johnston CI, Naitoh M, Burrell LM: Rational and pharmacology of angiotensin II receptor antagonists: current status and future issues. J Hypertens 1997, 15:S3-S6. (Pubitemid 28069988)
50. Vescovo G, Dalla Libera L, Serafini F, et al.: Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 1998, 98: 1742-1749.
51. Thurman PA, Kenedi P, Schmidt A, et al.: Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998, 98: 2037-2042.
52. Sugano M, Makino N, Yanago T: The effects of reninangiotensin system inhibition on aortic cholesterol content in cholesterol-feed rabbits. Atherosclerosis 1996, 127: 123-129.
53. Capers O 4th, Laursen JB, Fukui T, et al.: Vascular thrombin receptor regulation in hypertensive rats. Circ Res 1997, 80: 838-844.
54. Bentos A, Safar M: Aortic collagen, aortic stiffness, and AT1 receptors in experimental and human hypertension. Can J Physiol Pharmacol 1996, 74: 862-866.
55. Kim J, Benlries J, Naddler J: Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996, 226: 826-868.
56. Chobanian AV: Comparison of the effects of ACE inhibition and AT1 receptor blockade on atherosclerosis [abstract]. Am J Hypertens 1998, 11:38A.
57. Prescott MF, Webb RL, Reidy MA: Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol 1991, 139: 1291-1296.
58. Hickey H, Makdissi M, Hyland R, et al.: Perindopril treatment prevents the loss of endothelial NO function and development of neointima in rabbit. J Mol Cell Cardiol 1996, 28: 1985-1994.
59. Cachofeiro V, Maeso R, Munoz-Garcia R, Lahera V: The potential role of nitric oxide in angiotensin II receptor blockade. Blood Press 1996, 2(suppl): 29-35.
60. Touyz R, Schiffrin E: Effects of angiotensin II and endothelin- 1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension. Hypertension 1993, 22: 853-862.
61. Kerins D, Hao Q, Vaughan D: Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995, 96: 2515-2520.